Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Dimerix confirms ACTION3 trial remains powered for FSGS drug approval.

flag Dimerix Limited has confirmed its ACTION3 Phase 3 trial remains highly powered to detect a treatment effect on proteinuria, the primary endpoint. flag The FDA has approved this measure for full approval of its FSGS drug DMX-200, and the company will continue the trial to completion without an interim analysis. flag With adult enrollment finished and pediatric enrollment ongoing, the trial aims to secure approval for adults and adolescents.

8 Articles